Status:
UNKNOWN
The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)
Lead Sponsor:
Se-cure Pharmaceuticals Ltd.
Collaborating Sponsors:
Clalit Health Services
Conditions:
BPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS)
Eligibility:
MALE
50+ years
Phase:
NA
Brief Summary
A randomized, placebo controlled double-blind, 12-week treatment trial in men with moderate to severe symptoms of benign prostatic hyperplasia. The trail is about to examine the effect of Brizo® on re...
Detailed Description
1. Males in good general health 50 years of age and older, with symptoms of moderate to severe benign prostatic hyperplasia. 2. 120 patients: Study arm- min. 80 patients Placebo arm- min. 40 patients ...
Eligibility Criteria
Inclusion
- Males in good general health at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia
Exclusion
- Inability to complete the questionnaire.
- Patients with or suspected of having prostate cancer.
- Patients who have undergone a surgical procedure in the past year and / or who have taken medications or supplements in the past six months to treat BPH.
- Patients treated with drugs for kidney / urinary tract problems.
- Allergy to soy.
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05227508
Start Date
August 1 2022
End Date
June 1 2024
Last Update
July 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center - Clalit Health Services
Petah Tikva, Israel, 4941492